Roche (OTCQX:RHHBY) has received FDA clearance with a CLIA waiver for its cobas liat sexually transmitted infection, or STI, multiplex assay panels. The tests will be available exclusively in the U.S.

Q4 2024 Management View CEO Thomas Schinecker emphasized that 2024 was an "excellent year," with overall group sales growing 7%, driven by 9% growth in the base business. Pharma and diagnostics ...